HALLIBURTON CO — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that HALLIBURTON CO filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2010 | Dec 31, 2010 | $17.97B | Feb 17, 2011 |
| FY2009 | Dec 31, 2009 | $14.68B | Feb 17, 2010 |
| FY2009 | Dec 31, 2008 | $18.28B | Feb 17, 2010 |
| FY2009 | Dec 31, 2007 | $15.26B | Feb 17, 2010 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $20.62B | Feb 9, 2018 |
| FY2017 | Dec 31, 2016 | $15.89B | Feb 9, 2018 |
| FY2017 | Dec 31, 2015 | $23.63B | Feb 9, 2018 |
| FY2016 | Dec 31, 2014 | $32.87B | Feb 7, 2017 |
| FY2015 | Dec 31, 2013 | $29.40B | Feb 5, 2016 |
| FY2014 | Dec 31, 2012 | $28.50B | Feb 24, 2015 |
| FY2013 | Dec 31, 2011 | $24.83B | Feb 7, 2014 |
| FY2012 | Dec 31, 2010 | $17.97B | Feb 11, 2013 |
| FY2011 | Dec 31, 2009 | $14.68B | Feb 16, 2012 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.28B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $2.50B | Feb 6, 2026 |
| FY2025 | Dec 31, 2023 | $2.64B | Feb 6, 2026 |
| FY2024 | Dec 31, 2022 | $1.57B | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | $1.46B | Feb 6, 2024 |
| FY2022 | Dec 31, 2020 | ($2.95B) | Feb 7, 2023 |
| FY2021 | Dec 31, 2019 | ($1.13B) | Feb 4, 2022 |
| FY2020 | Dec 31, 2018 | $1.66B | Feb 5, 2021 |
| FY2019 | Dec 31, 2017 | ($463.00M) | Feb 11, 2020 |
| FY2018 | Dec 31, 2016 | ($5.76B) | Feb 13, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.26B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $3.82B | Feb 6, 2026 |
| FY2025 | Dec 31, 2023 | $4.08B | Feb 6, 2026 |
| FY2024 | Dec 31, 2022 | $2.71B | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | $1.80B | Feb 6, 2024 |
| FY2022 | Dec 31, 2020 | ($2.44B) | Feb 7, 2023 |
| FY2021 | Dec 31, 2019 | ($448.00M) | Feb 4, 2022 |
| FY2020 | Dec 31, 2018 | $2.47B | Feb 5, 2021 |
| FY2019 | Dec 31, 2017 | $1.37B | Feb 11, 2020 |
| FY2018 | Dec 31, 2016 | ($6.77B) | Feb 13, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $411.00M | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $426.00M | Feb 6, 2026 |
| FY2025 | Dec 31, 2023 | $408.00M | Feb 6, 2026 |
| FY2024 | Dec 31, 2022 | $345.00M | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | $321.00M | Feb 6, 2024 |
| FY2022 | Dec 31, 2020 | $309.00M | Feb 7, 2023 |
| FY2021 | Dec 31, 2019 | $404.00M | Feb 4, 2022 |
| FY2020 | Dec 31, 2018 | $390.00M | Feb 5, 2021 |
| FY2019 | Dec 31, 2017 | $360.00M | Feb 11, 2020 |
| FY2018 | Dec 31, 2016 | $329.00M | Feb 13, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.93B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $3.87B | Feb 6, 2026 |
| FY2025 | Dec 31, 2023 | $3.46B | Feb 6, 2026 |
| FY2024 | Dec 31, 2022 | $2.24B | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | $1.91B | Feb 6, 2024 |
| FY2022 | Dec 31, 2020 | $1.88B | Feb 7, 2023 |
| FY2021 | Dec 31, 2019 | $2.45B | Feb 4, 2022 |
| FY2020 | Dec 31, 2018 | $3.16B | Feb 5, 2021 |
| FY2019 | Dec 31, 2017 | $2.47B | Feb 11, 2020 |
| FY2018 | Dec 31, 2016 | ($1.70B) | Feb 13, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $25.01B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $25.59B | Feb 6, 2026 |
| FY2024 | Dec 31, 2023 | $24.68B | Feb 12, 2025 |
| FY2023 | Dec 31, 2022 | $23.26B | Feb 6, 2024 |
| FY2022 | Dec 31, 2021 | $22.32B | Feb 7, 2023 |
| FY2021 | Dec 31, 2020 | $20.68B | Feb 4, 2022 |
| FY2020 | Dec 31, 2019 | $25.38B | Feb 5, 2021 |
| FY2019 | Dec 31, 2018 | $25.98B | Feb 11, 2020 |
| FY2018 | Dec 31, 2017 | $25.09B | Feb 13, 2019 |
| FY2017 | Dec 31, 2016 | $27.00B | Feb 9, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.51B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $15.04B | Feb 6, 2026 |
| FY2024 | Dec 31, 2023 | $15.25B | Feb 12, 2025 |
| FY2023 | Dec 31, 2022 | $15.28B | Feb 6, 2024 |
| FY2022 | Dec 31, 2021 | $15.59B | Feb 7, 2023 |
| FY2021 | Dec 31, 2020 | $15.70B | Feb 4, 2022 |
| FY2020 | Dec 31, 2019 | $17.35B | Feb 5, 2021 |
| FY2019 | Dec 31, 2018 | $16.44B | Feb 11, 2020 |
| FY2018 | Dec 31, 2017 | $16.74B | Feb 13, 2019 |
| FY2017 | Dec 31, 2016 | $17.55B | Feb 9, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.46B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $10.51B | Feb 6, 2026 |
| FY2024 | Dec 31, 2023 | $9.39B | Feb 12, 2025 |
| FY2023 | Dec 31, 2022 | $7.95B | Feb 6, 2024 |
| FY2022 | Dec 31, 2021 | $6.71B | Feb 7, 2023 |
| FY2021 | Dec 31, 2020 | $4.97B | Feb 4, 2022 |
| FY2020 | Dec 31, 2019 | $8.01B | Feb 5, 2021 |
| FY2019 | Dec 31, 2018 | $9.52B | Feb 11, 2020 |
| FY2018 | Dec 31, 2017 | $8.32B | Feb 13, 2019 |
| FY2017 | Dec 31, 2016 | $9.41B | Feb 9, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.94B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $2.84B | Feb 6, 2026 |
| FY2025 | Dec 31, 2023 | $2.85B | Feb 6, 2026 |
| FY2024 | Dec 31, 2022 | $2.83B | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | $2.84B | Feb 6, 2024 |
| FY2022 | Dec 31, 2020 | $2.80B | Feb 7, 2023 |
| FY2021 | Dec 31, 2019 | $2.81B | Feb 4, 2022 |
| FY2020 | Dec 31, 2018 | $2.83B | Feb 5, 2021 |
| FY2019 | Dec 31, 2017 | $2.69B | Feb 11, 2020 |
| FY2018 | Dec 31, 2016 | $2.41B | Feb 13, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.04B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $14.33B | Feb 6, 2026 |
| FY2024 | Dec 31, 2023 | $12.54B | Feb 12, 2025 |
| FY2023 | Dec 31, 2022 | $10.57B | Feb 6, 2024 |
| FY2022 | Dec 31, 2021 | $9.71B | Feb 7, 2023 |
| FY2021 | Dec 31, 2020 | $8.69B | Feb 4, 2022 |
| FY2020 | Dec 31, 2019 | $11.99B | Feb 5, 2021 |
| FY2019 | Dec 31, 2018 | $13.74B | Feb 11, 2020 |
| FY2018 | Dec 31, 2017 | $12.67B | Feb 13, 2019 |
| FY2017 | Dec 31, 2016 | $14.14B | Feb 9, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.21B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $2.62B | Feb 6, 2026 |
| FY2024 | Dec 31, 2023 | $2.26B | Feb 12, 2025 |
| FY2023 | Dec 31, 2022 | $2.35B | Feb 6, 2024 |
| FY2022 | Dec 31, 2021 | $3.04B | Feb 7, 2023 |
| FY2022 | Dec 31, 2020 | $2.56B | Feb 7, 2023 |
| FY2022 | Dec 31, 2019 | $2.27B | Feb 7, 2023 |
| FY2021 | Dec 31, 2018 | $2.01B | Feb 4, 2022 |
| FY2020 | Dec 31, 2017 | $2.34B | Feb 5, 2021 |
| FY2019 | Dec 31, 2016 | $4.01B | Feb 11, 2020 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.16B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $7.16B | Feb 6, 2026 |
| FY2016 | Dec 31, 2015 | $15.35B | Feb 7, 2017 |
| FY2015 | Dec 31, 2014 | $7.78B | Feb 5, 2016 |
| FY2010 | Dec 31, 2010 | $3.82B | Feb 17, 2011 |
| FY2010 | Dec 31, 2009 | $4.57B | Feb 17, 2011 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | (6) | Feb 7, 2017 |
| FY2016 | Dec 31, 2015 | 0 | Feb 7, 2017 |
| FY2016 | Dec 31, 2014 | 4 | Feb 7, 2017 |
| FY2015 | Dec 31, 2013 | 2 | Feb 5, 2016 |
| FY2014 | Dec 31, 2012 | 2 | Feb 24, 2015 |
| FY2013 | Dec 31, 2011 | 3 | Feb 7, 2014 |
| FY2012 | Dec 31, 2010 | 2 | Feb 11, 2013 |
| FY2011 | Dec 31, 2009 | 1 | Feb 16, 2012 |
| FY2010 | Dec 31, 2008 | 2 | Feb 17, 2011 |
| FY2009 | Dec 31, 2007 | 3 | Feb 17, 2010 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | (1) | Feb 11, 2020 |
| FY2019 | Dec 31, 2018 | 1 | Feb 11, 2020 |
| FY2019 | Dec 31, 2017 | 0 | Feb 11, 2020 |
| FY2018 | Dec 31, 2016 | (6) | Feb 13, 2019 |
| FY2017 | Dec 31, 2015 | 0 | Feb 9, 2018 |
| FY2016 | Dec 31, 2014 | 4 | Feb 7, 2017 |
| FY2015 | Dec 31, 2013 | 2 | Feb 5, 2016 |
| FY2014 | Dec 31, 2012 | 2 | Feb 24, 2015 |
| FY2013 | Dec 31, 2011 | 3 | Feb 7, 2014 |
| FY2012 | Dec 31, 2010 | 2 | Feb 11, 2013 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 835.00M | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | 868.00M | Feb 6, 2026 |
| FY2024 | Dec 31, 2023 | 889.00M | Feb 12, 2025 |
| FY2023 | Dec 31, 2022 | 902.00M | Feb 6, 2024 |
| FY2022 | Dec 31, 2021 | 896.00M | Feb 7, 2023 |
| FY2021 | Dec 31, 2020 | 885.00M | Feb 4, 2022 |
| FY2020 | Dec 31, 2019 | 878.00M | Feb 5, 2021 |
| FY2019 | Dec 31, 2018 | 871.00M | Feb 11, 2020 |
| FY2018 | Dec 31, 2017 | 873.00M | Feb 13, 2019 |
| FY2017 | Dec 31, 2016 | 866.00M | Feb 9, 2018 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $579.00M | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $600.00M | Feb 6, 2026 |
| FY2025 | Dec 31, 2023 | $576.00M | Feb 6, 2026 |
| FY2024 | Dec 31, 2022 | $435.00M | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | $161.00M | Feb 6, 2024 |
| FY2022 | Dec 31, 2020 | $278.00M | Feb 7, 2023 |
| FY2021 | Dec 31, 2019 | $630.00M | Feb 4, 2022 |
| FY2020 | Dec 31, 2018 | $630.00M | Feb 5, 2021 |
| FY2019 | Dec 31, 2017 | $626.00M | Feb 11, 2020 |
| FY2018 | Dec 31, 2016 | $620.00M | Feb 13, 2019 |